Synapse - Craig Sauter

Results (10)

Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response

Meeting Abstract

Nastoupil, L. J.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López‐Guillermo, A.; Martínez‐López, J.; Novak, U.; Ribrag, V.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Allogeneic hematopoietic cell transplantation impacts on immune evasive mechanisms in relapsed/refractory diffuse large B‐cell lymphoma – A single center experience

Meeting Abstract

Sauter, C. S.; Lin, R. J.; Ho, C.; Devlin, S. M.; Maloy, M. A.; Perales, M.; Dahi, P. B.; Schoder, H.; Jakubowski, A. A.; Barker, J. N.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy

Meeting Abstract

Imber, B. S.; Palomba, M. L.; DeSelm, C.; Batlevi, C.; Dahi, P. B.; Giralt, S.; Noy, A. M.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Highly favorable outcomes with RT followed by ASCT in low/low‐intermediate secondary age adjusted IPI rel/ref DLBCL patients refractory to salvage chemotherapy

Meeting Abstract

Yang, J. C.; Chau, K. W.; Scordo, M.; Sauter, C. S.; Yahalom, J.
Hematological Oncology (2019)

Fulltext@MSK | Save

A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma

Meeting Abstract

Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Meeting Abstract

Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE